US EditionPublished • loading... • Updated
OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
OTR Therapeutics raised $100 million to enhance R&D and develop therapies targeting immunology, oncology, and inflammation, backed by global investors including Temasek.
- On Dec. 4, 2025 OTR Therapeutics emerged from stealth and completed a $100 million Series A financing as a biotechnology company transforming early-stage innovations into globally impactful therapies.
- Combining internal R&D with curated external assets, OTR Therapeutics built a scalable, capital-efficient model emphasizing scientific rigor and operational agility.
- Adding to its pipeline strategy, OTR received backing from True Light Capital, linked to Temasek, Pfizer Ventures, and Sirona Capital, with Zhui Chen, Shannon Chuai, and Yuan Shi as co-founders.
- Proceeds will fund development of pipeline programs in immunology & inflammation and oncology while expanding R&D hub capability to enable strategic partnerships and global clinical translation.
- Positioning itself for global development, OTR collaborates from its Shanghai's Zhangjiang Hi‑Tech Park R&D center with partners across the US, Europe and Asia, responding to a shifting landscape.
Insights by Ground AI
55 Articles
55 Articles
With backing from Pfizer and others, China startup raises $100M in new twist on licensing model
A new biotech has raised $100 million to build a mix of assets from inside and outside China, while developing its own drug candidates. The Shanghai-based startup, called OTR Therapeutics, is a new twist on ...
Coverage Details
Total News Sources55
Leaning Left4Leaning Right6Center19Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
14%
C 65%
R 21%
Factuality
To view factuality data please Upgrade to Premium
